Key result
Protease inhibitors can induce severe hypertriglyceridemia presenting as lipemia retinalis in HIV patients.
Why the study?
Lipemia retinalis is a rare but specific ophthalmic sign of severe hypertriglyceridemia associated with protease inhibitors in HIV-infected patients that may allow early diagnosis before life-threatening complications.
Case Report (n=2)
Lipemia retinalis can be a rare but specific presenting sign of severe hypertriglyceridemia in HIV patients on protease inhibitors, allowing for early diagnosis before life-threatening cardiovascular complications occur.
Answers are grounded in this paper and cite their sources.
Eye findings may flag severe hypertriglyceridemia in HIV patients on protease inhibitors; leaves open integrase inhibitor role and needs prospective study.
In Brief Purpose: To report two cases of lipemia retinalis in patients infected with human immunodeficiency virus on protease inhibitors with increased triglyceride levels. Methods: Retrospective review of medical records. Two patients infected with human immunodeficiency virus using protease inhibitors who were diagnosed with severe hypertriglyceridemia based on eye findings of lipemia retinalis. Results: One patient developed triglyceride level of >5,300 mg/dL after adding an integrase inhibitor to a regimen that included protease inhibitors. Hypertriglyceridemia was diagnosed after routine ophthalmic screening for cytomegalovirus retinitis revealed lipemia retinalis. Triglyceride levels improved significantly after both discontinuation of HIV medications and adjustment of cholesterol-lowering medications. Another patient developed triglyceride levels of >9,000 mg/dL while on protease inhibitors, which was also detected on routine retinal examination. Shortly after the diagnosis, he experienced acute coronary syndrome and cardiac arrest requiring plasmapheresis and emergent bypass surgery. Conclusion: Lipemia retinalis is rare but may be a presenting sign of severe hypertriglyceridemia in patients infected with human immunodeficiency virus. Recognition of this condition during the ophthalmic examination can lead to diagnosis and may allow for treatment before the development of life-threatening complications, such as pancreatitis and acute coronary syndrome. Medications used to treat human immunodeficiency viral infection, particularly protease inhibitors, can cause hypertriglyceridemia. Lipemia retinalis is a rare yet specific ophthalmic sign of severe hypertriglyceridemia (typically > 2,500 mg/dL). Recognition of this condition during ophthalmic examination can lead to diagnosis and treatment before the development of life-threatening complications, such as pancreatitis and acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2011) conducted a case report in Lipemia retinalis and severe hypertriglyceridemia in HIV (n=2). Protease inhibitors was evaluated on Development of severe hypertriglyceridemia and lipemia retinalis. Protease inhibitors in HIV-infected patients can cause severe hypertriglyceridemia (>5,300 and >9,000 mg/dL in two cases), presenting as lipemia retinalis on ophthalmic examination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: